|
Market Cap (5-Jun) $61,568,592 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (26-May) 11,577 (0.00%) (629th) |
|
52w High $0.425 |
52w Low $0.056 |
P/E - |
EPS -0.02 |
ATX released this announcement to the ASX on 24 January 2022, 8:13. The announcement is marked as price sensitive, and is 8 page(s) in length and 412.91kb in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.000% short sold according to ASIC data. It was ranked the 696th most shorted stock on the ASX. It is now ranked as the 629th most shorted stock on the ASX with 0.002% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| Quarterly Activities and Cashflow Reports - Dec 2021 Qtr | 24 January 2022, 8:13 |
| Notification regarding unquoted securities - ATX | 19 January 2022, 9:03 |
| Amplia Completes Manufacture of AMP945 for Planned Trials | 13 January 2022, 9:45 |
| Change in substantial holding | 23 December 2021, 16:29 |
You must be logged in to post a reply.
Amplia Therapeutics 